Printer Friendly

AMYLIN PHARMACEUTICALS INC. ANNOUNCES NOTICE OF PATENT ALLOWANCE

 AMYLIN PHARMACEUTICALS INC. ANNOUNCES NOTICE OF PATENT ALLOWANCE
 SAN DIEGO, Jan. 27 /PRNewswire/ -- Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering various pharmaceutical compositions of the hormone amylin. According to the company, the application also contains allowed claims to pharmaceutical compositions that include both amylin and insulin. These claims cover the use of amylin replacement therapy for reducing the risk of hypoglycemia, or abnormally low blood glucose, which is a serious problem associated with insulin therapy in juvenile diabetes.
 The company believes this Notice of Allowance is an important milestone in its efforts to establish its patent portfolio directed to medical uses of the newly discovered hormone, according to Howard E. (Ted) Greene, chairman and chief executive officer.
 "In the five years since amylin was discovered in the pancreases of adult diabetics, our company has focused its research efforts on understanding the role of this hormone in normal metabolism and in diabetes," Greene said. "These efforts have yielded numerous discoveries about the regulation of carbohydrate metabolism, discoveries which we believe can lead to important new medicines for diabetes and related disorders. We are delighted to receive this confirmation from the Patent Office that we are entitled to this patent coverage."
 Greene noted that the company is currently developing pharmaceutical compositions of amylin for acute treatment of severe hypoglycemia. It is also developing amylin and amylin agonists for administration to insulin-dependent (juvenile or "Type I") diabetics in combination with insulin.
 Amylin Pharmaceutical Inc. is a development stage pharmaceutical company working to commercialize novel therapeutic products for diabetes, obesity and related health problems. To date, Amylin Pharmaceuticals has filed or acquired more than 30 U.S. patent applications.
 -0- 1/27/92
 /CONTACT: Richard Keatinge or Linda Seaton of The Gable Group, 619-234-1300, for Amylin Pharmaceuticals Inc./
 (AMLN) CO: Amylin Pharmaceuticals Inc. ST: California IN: MTC SU:


JL-EH -- SD005 -- 3569 01/27/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:334
Previous Article:AMYLIN PHARMACEUTICALS ANNOUNCES FDA PERMISSION TO BEGIN CLINICAL TESTING
Next Article:UNIMED SIGNS AGREEMENT TO MARKET NEW PRODUCT LINE FOR SUPPORTIVE CARE OF HIV, AIDS AND CANCER PATIENTS
Topics:


Related Articles
AGOURON RECEIVES NOTICE OF U.S. PATENT ALLOWANCE COVERING ANTI-HIV DRUG VIRACEPT(TM) (AG1343)
Amylin Pharmaceuticals Acquires Rights to Third, Complementary, Potential Diabetes Drug Technology
Vion Receives Patent Notifications.
Antares Pharma Announces Notice of Allowance.
Sanofi-Aventis receives allowance on reissuance application for Lovenox '618 patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters